- Ryan Brady, EVP Head of Business Development at Evotec
- Cenk Cetin, VP Business Development at Evotec
- Jon Gunther, Sr. Director, Business Development at Just-Evotec Biologics
Mainstage Session | May 13th at 10:00 am
How New Pressures are Changing Biopharma Manufacturing
Linda Zuckerman, PhD, Global Head, Biotherapeutics at Just-Evotec Biologics
Linda ZuckermanEVP Global Head of Biotherapeutics
Linda brings over 20 years of biologics drug development experience to Just – Evotec Biologics that includes executive-level accountability for preclinical, clinical, and regulatory functions as well as business development and portfolio management activities. Prior to joining Just, Linda served as CEO of two small start-ups and was the President of ProFibrix, Inc., overseeing US-based biologics drug development activities as well as its operations.
Linda has also worked at Genentech and ZymoGenetics/BMS overseeing biologics development activities and contributed significantly to the approvals and commercialization of Raplixa (US & EU), Recothrom, and Raptiva and the filing many INDs in the areas of autoimmunity, hemostasis, and oncology. Linda received her Ph.D. in immunology from the University of Chicago and has an expertise in the regulatory aspects of the immunogenicity of biotherapeutics.